Laura Orlando, co-head of our Global IP practice and of Life Sciences in EMEA, has been interviewed by Managing Intellectual Property in an article focusing on the UPC and trends in the approach to opt-out being taken by the pharma sector.
Whilst several others quoted emphasised that the uncertainties surrounding the new system and the added risk of central revocation could lead many to protectively opt-out their key patents, Laura commented that some pharma patentees are taking a broader view, employing more strategic considerations, including the use of unitary patents. She said she was seeing a willingness from some to opt patents in and enforce them Europe-wide.
Read the article in Managing Intellectual Property here (subscription required).
Contact
Laura Orlando
Italy Managing Partner, Joint Global Head of Intellectual Property, EMEA Co-Head of Life Sciences, Milan
Key contacts
Laura Orlando
Italy Managing Partner, Joint Global Head of Intellectual Property, EMEA Co-Head of Life Sciences, Milan
Disclaimer
The articles published on this website, current at the dates of publication set out above, are for reference purposes only. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action.